Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

• DOI: 10.1016/j.xcrm.2023.101018
• Publication Date: 2023-03-27T06:11:57Z
• Authors: Jingyou Yu; Paul V. Thomas; Michaela Sciacca; Cindy Wu; Jinyan Liu; Xuan He; Jessica Miller; Nicole P. Hachmann; Nehalee Surve; Katherine McMahan; Catherine Jacob-D...; Olivia Powers; Kevin Hall; Julia Barrett; David Hope; Camille R. Mazurek; Tetyana Murdza; William C. Chang; Emily Golub; Phyllis A. Rees; Caroline E. Peterson; Agnes Hajduczki; Wei-Hung Chen; Elizabeth J. Mart...; Elizabeth Hussin; Camille Lange; Hua Gong; Gary R. Matyas; Mangala Rao; Mehul Suthar; Mona Boursiquot; Anthony Cook; Laurent Pessaint; Mark G. Lewis; Hanne Andersen; Diane L. Bolton; Nelson L. Michael; M. Gordon Joyce; Kayvon Modjarrad; Dan H. Barouch
• Keywords: Vaccines; Ad26COVS1; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Ferritins; Humans; Animals; Macaca; COVID-19; Nanoparticles; Article; 3. Good health

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective severe disease. However, immune correlates remain unknown. We report the immunogenicity and protective efficacy vaccine regimens consisting vector-based Ad26.COV2.S adjuvanted spike ferritin nanoparticle (SpFN) a high-dose, mismatched Omicron challenge in macaques. The SpFNx3 Ad26 + SpFNx2 elicit higher antibody responses than Ad26x3, whereas Ad26x3 induce CD8 T cell SpFNx3. regimen elicits highest CD4 responses. All three suppress peak day 4 viral loads tract, which correlate with both humoral cellular This study demonstrates that homologous heterologous involving SpFN provide robust